Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity

Experimental and Therapeutic Medicine

Volumn 2, Issue 4, 2011, Pages 731-735

  Busquets, Sílvia ^a   Toledo, Míriam ^a   Sirisi, Sònia ^a   Orpí, Marcel ^a   Serpe, Roberto ^b,c   Coutinho, Joana ^a   Martínez, Raquel ^a   Argilés, Josep M ^a   López Soriano, Francisco J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c University of Cagliari ^*  (Italy)

Author keywords

2 agonists; Cancer cachexia; Formoterol; Muscle force; Physical activity; Skeletal muscle

Indexed keywords

FORMOTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES HEPATOMA; CACHEXIA; CONTROLLED STUDY; GRIP STRENGTH; MALE; MUSCLE ATROPHY; MUSCLE FORCE; NONHUMAN; PHYSICAL ACTIVITY; PHYSICAL PERFORMANCE; RAT; TREATMENT DURATION; WEIGHT REDUCTION;

EID: 79958046995     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.260     Document Type: Article

References (32)

1. Warren S: The immediate causes of death in cancer. Am J Med Sci 184: 610-615, 1932.
2. Argiles JM, Alvarez B and Lopez-Soriano FJ: The metabolic basis of cancer cachexia. Med Res Rev 17: 477-498, 1997.
3. Argiles JM and Lopez-Soriano FJ: Why do cancer cells have such a high glycolytic rate? Med Hypotheses 32: 151-155, 1990.
4. Harvey KB, Bothe A Jr and Blackburn GL: Nutritional assessment and patient outcome during oncological therapy. Cancer 43: 2065-2069, 1979.
5. Nixon DW, Heymsfeld SB, Cohen AE, et al: Protein-calorie undernutrition in hospitalized cancer patients. Am J Med 68: 683-690, 1980.
6. DeWys W: Management of cancer cachexia. Semin Oncol 12: 452-460, 1985.
7. Argiles JM, Garcia-Martinez C, Llovera M and Lopez-Soriano FJ: The role of cytokines in muscle wasting: its relation with cancer cachexia. Med Res Rev 12: 637-652, 1992.
8. Van Royen M, Carbo N, Busquets S, et al: DNA fragmentation occurs in skeletal muscle during tumor growth: a link with cancer cachexia? Biochem Biophys Res Commun 270: 533-537, 2000.
9. Kim YS and Sainz RD: Beta-adrenergic agonists and hypertrophy of skeletal muscles. Life Sci 50: 397-407, 1992.
10. Stock MJ and Rothwell NJ: Effects of beta-adrenergic agonists on metabolism and body composition. In: Control and Manipulation of Animal Growth. Buttery PJ, Hayes NB and Lindsay DB (eds.) Butterworths, London, pp 249-257, 1985.
11. Agbenyega ET and Wareham AC: Effect of clenbuterol on skeletal muscle atrophy in mice induced by the glucocorticoid dexamethasone. Comp Biochem Physiol Comp Physiol 102: 141-145, 1992.
12. Rajab P, Fox J, Riaz S, Tomlinson D, Ball D and Greenhaff PL: Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat. Am J Physiol Regul Integr Comp Physiol 279: R1076-R1081, 2000.
13. Hinkle RT, Hodge KM, Cody DB, Sheldon RJ, Kobilka BK and Isfort RJ: Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve 25: 729-734, 2002.
14. Wineski LE, von Deutsch DA, Abukhalaf IK, Pitts SA, Potter DE and Paulsen DF: Muscle-specifc effects of hindlimb suspension and clenbuterol in mature male rats. Cells Tissues Organs 171: 188-198, 2002.
15. Yang YT and McElligott MA: Multiple actions of beta-adren-ergic agonists on skeletal muscle and adipose tissue. Biochem J 261: 1-10, 1989.
16. Mersmann HJ: Overview of the effects of beta-adrenergic receptor agonists on animal growth including mechanisms of action. J Anim Sci 76: 160-172, 1998.
17. Anderson GP: Pharmacology of formoterol: an innovative bronchodilator. Agents Actions Suppl 34: 97-115, 1991.
18. Mahler DA: The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 110: S298-S303, 2002.
19. Busquets S, Figueras MT, Fuster G, et al: Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 64: 6725-6731, 2004.
20. Tessitore L, Costelli P, Bonetti G and Baccino FM: Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. Arch Biochem Biophys 306: 52-58, 1993.
21. Sinis N, Guntinas-Lichius O, Irintchev A, et al: Manual stimulation of forearm muscles does not improve recovery of motor function after injury to a mixed peripheral nerve. Exp Brain Res 185: 469-483, 2008.
22. Zangarelli A, Chanseaume E, Morio B, et al: Synergistic effects of caloric restriction with maintained protein intake on skeletal muscle performance in 21-month-old rats: a mitochondria-mediated pathway. FASEB J 20: 2439-2450, 2006.
23. Fuster G, Busquets S, Ametller E, et al: Are peroxisome prolif-erator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists. Cancer Res 67: 6512-6519, 2007.
24. Costelli P, Garcia-Martinez C, Llovera M, et al: Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest 95: 2367-2372, 1995.
25. Ametller E, Busquets S, Fuster G, et al: Formoterol may activate rat muscle regeneration during cancer cachexia. Insciences J 1: 1-17, 2011.
26. Lanigan C, Howes TQ, Borzone G, Vianna LG and Moxham J: The effects of beta 2-agonists and caffeine on respiratory and limb muscle performance. Eur Respir J 6: 1192-1196, 1993.
27. Signorile JF, Banovac K, Gomez M, Flipse D, Caruso JF and Lowensteyn I: Increased muscle strength in paralyzed patients after spinal cord injury: effect of beta-2 adrenergic agonist. Arch Phys Med Rehabil 76: 55-58, 1995.
28. Marzabal M, Garcia-Martinez C, Comas J, Lopez-Soriano FJ and Argiles JM: A fow cytometric study of the rat Yoshida AH-130 ascites hepatoma. Cancer Lett 72: 169-173, 1993.
29. Toledo M, Busquets S, Sirisi S, et al: Cancer cachexia: physical activity and muscle force in tumour-bearing rats. Oncol Rep 25: 189-193, 2011.
30. Argiles JM, Busquets S, Toledo M and Lopez-Soriano FJ: The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 3: 263-268, 2009.
31. Llovera M, Garcia-Martinez C, Lopez-Soriano J, et al: Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol 142: 183-189, 1998.
32. Argiles JM, Busquets S and Lopez-Soriano FJ: Cytokines as mediators and targets for cancer cachexia. Cancer Treat Res 130: 199-217, 2006.